Medical Search Australia Trusted by 250,000+ buyers

New drug released for children suffering from ADHD disorder

17 April, 2007

A new drug for the treatment of attention deficit hyperactivity disorder (ADHD) will be listed from 1 July 2007 on the Pharmaceutical Benefits Scheme (PBS).

The drug, Strattera® (atomoxetine), will provide treatment for children between the ages of six and 18 years who cannot take stimulants.

ADHD is a behavioural and developmental disorder that affect young children. The main symptoms of ADHD – inattention, hyperactivity and impulsivity – contribute to adverse academic and social behaviour, which can have consequences that persist throughout adolescence and into adulthood.

Treatment for ADHD normally involves stimulant therapy, so the listing of Strattera® on the PBS will especially benefit those who are unable to take stimulants.

About 18,000 people will commence Strattera® in the first full financial year of listing.

The listing of Strattera® will add around $101.2 million to PBS and Repatriation Pharmaceutical Benefits Scheme expenditure between 2007-08 and 2010-11.

Have your say...

We welcome thoughtful comments from readers
Reload characters
Type the characters you see in this box. This helps us prevent automated programs from sending spam.